ABCSG 38/Lorelei Trial Summary

A phase II, randomized, double-blind study of neoadjuvant letrozole + GDC-0032 vs. letrozole + placebo in postmenopausal women with ER+/ HER2- negative primary breast cancer

Start: 09/2014
Coordinating investigator: Dubsky, Peter; Vienna
Sample size: 330
Design:
(Click to enlarge)
ABCSG-38